RECURRENT HEAD AND NECK CANCER
Clinical trials for RECURRENT HEAD AND NECK CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK CANCER trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to boost immune attack against HPV-driven head and neck cancer
Disease control OngoingThis phase 3 study tests whether adding an experimental immunotherapy (PDS0101) to standard pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer or delay cancer growth. About 252 participants will receive either the combination or pembrolizumab…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated May 26, 2026 11:35 UTC
-
New drug combo shows promise in fighting tough head and neck cancers
Disease control OngoingThis study tests whether adding ramucirumab to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has come back or spread. The trial includes 37 adults whose tumors have a specific marker (PD-L1 positi…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 11:27 UTC